ORIGINAL RESEARCH article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1644388
Prognostic Modeling for Diffuse Midline Glioma: Development and Validation of a Risk Stratification Nomogram Using SEER and Institutional Cohorts
Provisionally accepted
- Department of Radiotherapy, Second Hospital of Hebei Medical University, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Diffuse midline glioma (DMG) is a rare and highly aggressive central nervous system tumor with limited treatment options and poor survival outcomes. Reliable prognostic models are urgently needed to guide risk-adapted therapy. Methods We retrospectively analyzed 409 DMG patients from the SEER database (2018–2021). Independent prognostic factors were identified using multivariate Cox regression analysis. A nomogram was developed to estimate overall survival, and its performance was evaluated using the concordance index (C-index), time-dependent ROC curves, calibration plots. Risk stratification was based on nomogram total scores. Subgroup survival comparisons were conducted using Kaplan–Meier and log-rank tests. External validation was performed using an independent institutional cohort of 22 patients. Results An age-dependent anatomical distribution was observed: brainstem tumors predominated in children, while non-brainstem tumors were more common in adults. Multivariate Cox regression identified older age, higher household income, and cerebellar location as independent prognostic factors. These variables were incorporated into a nomogram that demonstrated good discriminative ability and calibration. Based on total risk scores, patients were stratified into high-and low-risk groups with significantly different survival outcomes. Combined chemoradiotherapy significantly improved survival compared to radiotherapy or chemotherapy alone, while chemotherapy alone showed no added benefit. Surgical resection extent was not associated with prognosis. In an external validation cohort of 22 patients, survival was better in the low-risk group than in the high-risk group, although the difference was not statistically significant (P=0.188). Conclusion This study presents the first large-scale, SEER-based nomogram for DMG, offering reliable prognostic stratification and reinforcing the survival benefit of combined chemoradiotherapy. The model's clinical utility is further supported by real-world institutional validation, underscoring its potential to inform individualized treatment strategies in DMG.
Keywords: diffuse midline glioma, Prognostic Nomogram, survival analysis, Radiotherapy, chemotherapy
Received: 10 Jun 2025; Accepted: 14 Oct 2025.
Copyright: © 2025 Zhang, Zhou, Han, Lou and Xue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaoying Xue, xxy0636@hebmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.